The dominant source of thromboembolism in heart comes from the left atrial appendage
(LAA). An occluder can close LAA and significantly reduce the risk of strokes, particularly for …

The next-generation closure device for interventional treatment of congenital heart disease
is regarded to be biodegradable, yet the corresponding biomaterial technique is still …

Degradable heart occluders are a promising replacement for currently clinically used non-
degradable ones without concerns about the complications caused by the persistent residue …

Despite significant advances in numerous fields of biofabrication, clinical application of
biomaterials combined with bioactive molecules and/or cells largely remains a promise in an …

Cardiac septal defect is the most prevalent congenital heart disease and is typically treated
with open‐heart surgery under cardiopulmonary bypass. Since the 1990s, with the …

Although the use of bioabsorbable occluder is expected to reduce the risk of metal occluder-
related complications, it has not been approved due to incomplete degradation and new …

Transcatheter intervention has been the preferred treatment for congenital structural heart
diseases by implanting occluders into the heart defect site through minimally invasive …

Atrial septal defect (ASD) is the third most common type of structural congenital heart defect.
Patent foramen ovale (PFO) is an anatomical anomaly in up to 25% of the general …

Background Both percutaneous and perventricular device closures of perimembranous
ventricular septal defects (Pm-VSDs) are alternatives to surgical procedures, but they all …

Percutaneous interventions have transformed management of many congenital heart
lesions from fetal life through adulthood. This article is the second of a two-part review of …